Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Is Teva’s US Decline In Q3 Evidence Of A Broader Downward Trend?

Third Quarter Numbers Follow Sandoz’ View Of ‘Challenging Environment’

Executive Summary

Teva faced questions about the current environment in the US for generics, following weakness in its numbers and in those of rival Sandoz during the third quarter. Management remains “very committed to the US generics segment,” after sales dropped by 7%.

You may also be interested in...



NYSE Gives Lannett Six Months To Meet Standards

US firm has received a notice of non-compliance from NYSE due to price of company’s shares. Lannett insists there is no immediate impact, but it is evaluating options, including “transactions that are subject to approval of Lannett’s stockholders.”

New York Exchange Gives Lannett Six Months To Meet Standards

US-based manufacturer Lannett has received a notice of non-compliance from the NYSE due to price of the company’s share. Lannett insists there is no immediate impact, but the firm is evaluating options, including “transactions that are subject to approval of Lannett’s stockholders.”

Induced Infringement And Price Fixing Among Legal Headlines In 2021

In 2021, courts across the US and beyond continued to weigh key patent litigation fights, alongside the thorny issue of induced infringement via label carve outs and controversial charges for generic price fixing.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151362

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel